Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
15/05/2025 21:21
Outlook Therapeutics Inc OTLK.OQ reported a quarterly adjusted loss of 40 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.55. The mean expectation of six analysts for the quarter was for a loss of 60 cents per share. Wall Street expected results to range from -93 cents to -45 cents per share. Reported revenue was zero; analysts expected $702.60 thousand. Outlook Therapeutics Inc's reported EPS for the quarter was a loss of $1.50. The company reported a quarterly loss of $46.36 million. Outlook Therapeutics Inc shares had risen by 43.0% this quarter and lost 7.7% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 1.1% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Outlook Therapeutics Inc is $9.50 This summary was machine generated from LSEG data May 15 at 08:20 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.60 | -0.40 | Beat |
| Dec. 31 2024 | -0.77 | 0.72 | Beat |
| Sep. 30 2024 | -0.83 | 0.76 | Beat |
| Jun. 30 2024 | -1.00 | -0.83 | Beat |
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce